dc.creatorBravo, Dalibel
dc.creatorSalduz, Ahmet
dc.creatorShogren, Kristen L.
dc.creatorOkuno, Madison N.
dc.creatorHerrick, James L.
dc.creatorOkuno, Scott H.
dc.creatorGalindo, Mario A.
dc.creatorvan Wijnen, Andre J.
dc.creatorYaszemski, Michael J.
dc.creatorMaran, Avudaiappan
dc.date.accessioned2018-12-20T14:22:47Z
dc.date.available2018-12-20T14:22:47Z
dc.date.created2018-12-20T14:22:47Z
dc.date.issued2018
dc.identifierGene, Volumen 674,
dc.identifier18790038
dc.identifier03781119
dc.identifier10.1016/j.gene.2018.06.059
dc.identifierhttps://repositorio.uchile.cl/handle/2250/155752
dc.description.abstract© 2018 Osteosarcoma is a malignant bone tumor that occurs mainly in children and adolescents. Because Wnt signaling has been implicated in the pathogenesis of osteosarcoma, we have investigated the circulating and local levels of the Wnt antagonist protein, Secreted Frizzled Related Protein (sFRP) 3, in osteosarcoma patients. Enzyme linked immunosorbent assay (ELISA) analysis of 67 osteosarcoma and age-matched non-diseased control sera showed that sFPR3 protein levels were significantly lower in osteosarcoma than in normal. Analysis of tumor and adjacent normal tissues (9 pairs) from osteosarcoma patients showed a decrease in sFRP3 expression in 5 out of 9 tumor samples compared to normal tissues. Furthermore, immunohistochemical analysis of tissue microarray revealed a significant decrease in sFRP3 levels in tumor compared to normal bone. RNA sequencing analysis in osteosarcoma cells shows suppression of sFRP3 and concomitant expression of multiple Wnt family members mediating canonic
dc.languageen
dc.publisherElsevier B.V.
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Chile
dc.sourceGene
dc.subjectFrzb
dc.subjectOsteosarcoma
dc.subjectsFRP3
dc.subjectWnt
dc.titleDecreased local and systemic levels of sFRP3 protein in osteosarcoma patients
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución